231 related articles for article (PubMed ID: 23272171)
1. Dexamethasone reduces sensitivity to cisplatin by blunting p53-dependent cellular senescence in non-small cell lung cancer.
Ge H; Ni S; Wang X; Xu N; Liu Y; Wang X; Wang L; Song D; Song Y; Bai C
PLoS One; 2012; 7(12):e51821. PubMed ID: 23272171
[TBL] [Abstract][Full Text] [Related]
2. Dexamethasone alleviates pemetrexed-induced senescence in Non-Small-Cell Lung Cancer.
Ge H; Ke J; Xu N; Li H; Gong J; Li X; Song Y; Zhu H; Bai C
Food Chem Toxicol; 2018 Sep; 119():86-97. PubMed ID: 29753869
[TBL] [Abstract][Full Text] [Related]
3. Annexin A2 contributes to cisplatin resistance by activation of JNK-p53 pathway in non-small cell lung cancer cells.
Feng X; Liu H; Zhang Z; Gu Y; Qiu H; He Z
J Exp Clin Cancer Res; 2017 Sep; 36(1):123. PubMed ID: 28886730
[TBL] [Abstract][Full Text] [Related]
4. WP1130 attenuates cisplatin resistance by decreasing P53 expression in non-small cell lung carcinomas.
Wang X; Bao Y; Dong Z; Chen Q; Guo H; Ziang C; Shao J
Oncotarget; 2017 Jul; 8(30):49033-49043. PubMed ID: 28446729
[TBL] [Abstract][Full Text] [Related]
5. Upregulation of Long Noncoding RNA (lncRNA) X-Inactive Specific Transcript (XIST) is Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer (NSCLC) by Downregulating MicroRNA-144-3p.
Tian LJ; Wu YP; Wang D; Zhou ZH; Xue SB; Zhang DY; Wei YG; Liu W
Med Sci Monit; 2019 Oct; 25():8095-8104. PubMed ID: 31659146
[TBL] [Abstract][Full Text] [Related]
6. Pentraxin 3 acts as a functional effector of Akt/NF-κB signaling to modulate the progression and cisplatin-resistance in non-small cell lung cancer.
Li Y; Song X; Niu J; Ren M; Tang G; Sun Z; Kong F
Arch Biochem Biophys; 2021 Apr; 701():108818. PubMed ID: 33617838
[TBL] [Abstract][Full Text] [Related]
7. Up-regulation of miR-146a increases the sensitivity of non-small cell lung cancer to DDP by downregulating cyclin J.
Shi L; Xu Z; Wu G; Chen X; Huang Y; Wang Y; Jiang W; Ke B
BMC Cancer; 2017 Feb; 17(1):138. PubMed ID: 28202053
[TBL] [Abstract][Full Text] [Related]
8. Cisplatin-enriching cancer stem cells confer multidrug resistance in non-small cell lung cancer via enhancing TRIB1/HDAC activity.
Wang L; Liu X; Ren Y; Zhang J; Chen J; Zhou W; Guo W; Wang X; Chen H; Li M; Yuan X; Zhang X; Yang J; Wu C
Cell Death Dis; 2017 Apr; 8(4):e2746. PubMed ID: 28406482
[TBL] [Abstract][Full Text] [Related]
9. Membrane-Bound CD40L Promotes Senescence and Initiates Senescence-Associated Secretory Phenotype via NF-κB Activation in Lung Adenocarcinoma.
Xu W; Li Y; Yuan WW; Yin Y; Song WW; Wang Y; Huang QQ; Zhao WH; Wu JQ
Cell Physiol Biochem; 2018; 48(4):1793-1803. PubMed ID: 30078020
[TBL] [Abstract][Full Text] [Related]
10. Chronic p27
Patki M; McFall T; Rosati R; Huang Y; Malysa A; Polin L; Fielder A; Wilson MR; Lonardo F; Back J; Li J; Matherly LH; Bepler G; Ratnam M
Sci Rep; 2018 Oct; 8(1):16006. PubMed ID: 30375484
[TBL] [Abstract][Full Text] [Related]
11. TNFAIP8 promotes the proliferation and cisplatin chemoresistance of non-small cell lung cancer through MDM2/p53 pathway.
Xing Y; Liu Y; Liu T; Meng Q; Lu H; Liu W; Hu J; Li C; Cao M; Yan S; Huang J; Wang T; Cai L
Cell Commun Signal; 2018 Jul; 16(1):43. PubMed ID: 30064446
[TBL] [Abstract][Full Text] [Related]
12. Mutations of p53 and KRAS activate NF-κB to promote chemoresistance and tumorigenesis via dysregulation of cell cycle and suppression of apoptosis in lung cancer cells.
Yang L; Zhou Y; Li Y; Zhou J; Wu Y; Cui Y; Yang G; Hong Y
Cancer Lett; 2015 Feb; 357(2):520-6. PubMed ID: 25499080
[TBL] [Abstract][Full Text] [Related]
13. Dexamethasone-induced cisplatin and gemcitabine resistance in lung carcinoma samples treated ex vivo.
Gassler N; Zhang C; Wenger T; Schnabel PA; Dienemann H; Debatin KM; Mattern J; Herr I
Br J Cancer; 2005 Mar; 92(6):1084-8. PubMed ID: 15756274
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory effects of polyphyllins I and VII on human cisplatin-resistant NSCLC via p53 upregulation and CIP2A/AKT/mTOR signaling axis inhibition.
Feng FF; Cheng P; Sun C; Wang H; Wang W
Chin J Nat Med; 2019 Oct; 17(10):768-777. PubMed ID: 31703757
[TBL] [Abstract][Full Text] [Related]
15. A Combination RNAi-Chemotherapy Layer-by-Layer Nanoparticle for Systemic Targeting of KRAS/P53 with Cisplatin to Treat Non-Small Cell Lung Cancer.
Gu L; Deng ZJ; Roy S; Hammond PT
Clin Cancer Res; 2017 Dec; 23(23):7312-7323. PubMed ID: 28912139
[No Abstract] [Full Text] [Related]
16. The USP10-HDAC6 axis confers cisplatin resistance in non-small cell lung cancer lacking wild-type p53.
Hu C; Zhang M; Moses N; Hu CL; Polin L; Chen W; Jang H; Heyza J; Malysa A; Caruso JA; Xiang S; Patrick S; Stemmer P; Lou Z; Bai W; Wang C; Bepler G; Zhang XM
Cell Death Dis; 2020 May; 11(5):328. PubMed ID: 32382008
[TBL] [Abstract][Full Text] [Related]
17. Circular RNA PRMT5 confers cisplatin-resistance via miR-4458/REV3L axis in non-small-cell lung cancer.
Pang J; Ye L; Zhao D; Zhao D; Chen Q
Cell Biol Int; 2020 Dec; 44(12):2416-2426. PubMed ID: 32808744
[TBL] [Abstract][Full Text] [Related]
18. Increasing p53 protein sensitizes non-small cell lung cancer to paclitaxel and cisplatin in vitro.
Guntur VP; Waldrep JC; Guo JJ; Selting K; Dhand R
Anticancer Res; 2010 Sep; 30(9):3557-64. PubMed ID: 20944137
[TBL] [Abstract][Full Text] [Related]
19. LncRNA TATDN1 contributes to the cisplatin resistance of non-small cell lung cancer through TATDN1/miR-451/TRIM66 axis.
Wang L; Shang X; Feng Q
Cancer Biol Ther; 2019; 20(3):261-271. PubMed ID: 30481109
[TBL] [Abstract][Full Text] [Related]
20. Downregulated long non-coding RNA TRPM2-AS inhibits cisplatin resistance of non-small cell lung cancer cells via activation of p53- p66shc pathway.
Ma LY; Xie XW; Ma L; Pang JL; Xiong XM; Zheng HD; Shen XL; Wen ZG; Wang HY
Eur Rev Med Pharmacol Sci; 2017 Jun; 21(11):2626-2634. PubMed ID: 28678322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
